Department of Sports Science, College of Life Science and Nano Technology, Hannam University, Daejeon, South Korea.
Mitohormesis Research Center, Yonsei University Wonju College of Medicine, Wonju, South Korea.
Sci Rep. 2024 Nov 11;14(1):27527. doi: 10.1038/s41598-024-77719-6.
Mitochondrial dysfunction with oxidative stress contributes to metabolic dysfunction-associated steatotic liver disease (MASLD) progression. We aimed to evaluate the fibrosis predictive efficacy of a novel non-invasive diagnostic panel using metabolic stress biomarkers. From a population-based general cohort, 144 subjects with MASLD were recruited in the development group and underwent magnetic resonance imaging-based liver examinations, anthropometric and laboratory tests. As an external validation group, 41 patients enrolled in a biopsy-evaluated MASLD cohort participated in this study. Liver fat content and stiffness were measured by magnetic resonance (MR) imaging-proton density fat fraction and MR elastography (MRE), respectively. Serologic stress biomarkers were quantitated by ELISA. Multivariate regression showed that waist-to-height ratio, growth differentiation factor-15 (GDF15), γ-glutamyltransferase, decorin, and alkaline-phosphatase were independent predictors of hepatic fibrosis (rank-ordered by Wald). The area under receiver-operator characteristics curve [AUROC (95% CI)) of the metabolic stress index for fibrosis (MSI-F) was 0.912 (0.85‒0.98) and 0.977 (0.92‒1.00) in development and validation groups, respectively. MSI-F also had better diagnostic accuracy (82.6‒92.4%) than other fibrosis indices in the both study cohorts. MSI-F consistently differentiated fibrosis severities across cohorts of MRE-evaluated general population and biopsy-proven patients with MASLD, while other indices showed no or less discrimination. MSI-F, as a novel non-invasive index based on a stress-stimulated protective hormone GDF15 and decorin, effectively predicted hepatic fibrosis. Furthermore, MSI-F may serve as pre-screening tool to increase the population that could be excluded from further evaluation, reducing unnecessary invasive investigations more effectively than other indices.
线粒体功能障碍伴氧化应激导致代谢相关脂肪性肝病(MASLD)进展。我们旨在评估使用代谢应激生物标志物的新型非侵入性诊断小组的纤维化预测效果。从基于人群的一般队列中,招募了 144 名 MASLD 患者作为开发组,并进行了磁共振成像(MRI)检查、人体测量和实验室检查。作为外部验证组,有 41 名 MASLD 患者参与了这项研究。通过磁共振(MR)成像质子密度脂肪分数和 MR 弹性成像(MRE)分别测量肝脂肪含量和硬度。通过 ELISA 定量血清应激生物标志物。多元回归显示,腰围与身高比、生长分化因子 15(GDF15)、γ-谷氨酰转移酶、核心蛋白聚糖和碱性磷酸酶是纤维化的独立预测因子(按 Wald 排序)。代谢应激指数纤维化(MSI-F)的受试者工作特征曲线下面积[AUROC(95%CI)]在开发组和验证组中分别为 0.912(0.85-0.98)和 0.977(0.92-1.00)。MSI-F 在两个研究队列中的纤维化诊断准确性也优于其他纤维化指数(82.6-92.4%)。MSI-F 在 MRE 评估的一般人群和 MASLD 活检证实患者的纤维化严重程度方面具有更好的区分能力,而其他指数则没有或较少的区分能力。MSI-F 作为一种基于应激刺激保护激素 GDF15 和核心蛋白聚糖的新型非侵入性指数,有效地预测了肝纤维化。此外,MSI-F 可能作为一种筛查工具,增加可以从进一步评估中排除的人群,比其他指数更有效地减少不必要的侵入性检查。